Nothing Special   »   [go: up one dir, main page]

ECSP13012997A - Antídotos anticoagulantes - Google Patents

Antídotos anticoagulantes

Info

Publication number
ECSP13012997A
ECSP13012997A ECSP13012997A ECSP13012997A EC SP13012997 A ECSP13012997 A EC SP13012997A EC SP13012997 A ECSP13012997 A EC SP13012997A EC SP13012997 A ECSP13012997 A EC SP13012997A
Authority
EC
Ecuador
Prior art keywords
antidotes
anticoagulant
anticoagulant antidotes
anticoagulants
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Norbert Hauel
Sanjaya Singh
Ryn Joanne Van
Tobias Litzenburger
Keith Canada
Alisa Waterman
Robert Copenhaver
Christopher Ronald Sarko
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP13012997A publication Critical patent/ECSP13012997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a moléculas de anticuerpo contra anticoagulantes, en particular dabigatran, y a su uso como antídotos de dichos anticoagulantes.
ECSP13012997 2011-03-30 2013-10-25 Antídotos anticoagulantes ECSP13012997A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161469207P 2011-03-30 2011-03-30

Publications (1)

Publication Number Publication Date
ECSP13012997A true ECSP13012997A (es) 2013-12-31

Family

ID=45876804

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012997 ECSP13012997A (es) 2011-03-30 2013-10-25 Antídotos anticoagulantes

Country Status (22)

Country Link
US (2) US8821871B2 (es)
EP (1) EP2691156A1 (es)
JP (1) JP2014515740A (es)
KR (1) KR20140009437A (es)
CN (1) CN103476459A (es)
AP (1) AP2013007046A0 (es)
AR (1) AR085758A1 (es)
BR (1) BR112013025031A2 (es)
CA (1) CA2827787A1 (es)
CL (1) CL2013002551A1 (es)
CO (1) CO6771448A2 (es)
EA (1) EA201301090A1 (es)
EC (1) ECSP13012997A (es)
IL (1) IL227653A0 (es)
MA (1) MA34978B1 (es)
MX (1) MX2013011092A (es)
PE (1) PE20140964A1 (es)
SG (1) SG193552A1 (es)
TN (1) TN2013000388A1 (es)
TW (1) TW201302796A (es)
UY (1) UY33994A (es)
WO (1) WO2012130834A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3604339T3 (pl) 2011-01-14 2021-12-27 The Regents Of The University Of California Terapeutyczne przeciwciała przeciwko białku ror-1 i sposoby ich zastosowania
SI2785700T1 (sl) 2011-11-29 2016-09-30 Perosphere, Inc. Antikoagulantna reverzna sredstva
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
EA036162B1 (ru) * 2013-07-30 2020-10-08 Янссен Сайенсиз Айрлэнд Юси Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
EP3060583A1 (en) * 2013-10-25 2016-08-31 Boehringer Ingelheim International GmbH Anticoagulant antidotes
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
EP3784281A4 (en) * 2018-04-27 2022-02-16 Seattle Children's Hospital d/b/a Seattle Children's Research Institute IN VIVO GENE THERAPY USING ADMINISTRATION OF A LENTIVIRAL GENE CONSTRUCT

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
RU2128709C1 (ru) 1992-01-23 1999-04-10 Мерк Патент Гмбх Способ получения димерного одноцепочечного слитого белка (варианты)
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
EP1087013B1 (en) 1992-08-21 2009-01-07 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
AU678483B2 (en) 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
CA2288992C (en) 1997-04-30 2012-06-12 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP2298355A3 (en) 2000-04-12 2011-06-29 Human Genome Sciences, Inc. Albumin fusion proteins
CN1268394C (zh) 2001-01-17 2006-08-09 特鲁比昂药品公司 结合域－免疫球蛋白融合蛋白
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
EP2301967A3 (en) 2002-11-08 2011-07-13 Ablynx N.V. Single domain antibodies for nasal administration
KR102271404B1 (ko) 2007-09-28 2021-07-02 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
DK2470187T3 (da) 2009-08-24 2013-10-28 Boehringer Ingelheim Int Nødintervention med aktivt kul ved dabigatranetexilatoverdosering
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑

Also Published As

Publication number Publication date
IL227653A0 (en) 2013-09-30
TW201302796A (zh) 2013-01-16
EA201301090A1 (ru) 2014-05-30
SG193552A1 (en) 2013-11-29
MA34978B1 (fr) 2014-03-01
AR085758A1 (es) 2013-10-23
UY33994A (es) 2012-09-28
CN103476459A (zh) 2013-12-25
JP2014515740A (ja) 2014-07-03
NZ613543A (en) 2015-07-31
WO2012130834A1 (en) 2012-10-04
BR112013025031A2 (pt) 2017-08-01
US8821871B2 (en) 2014-09-02
CL2013002551A1 (es) 2014-02-14
US20140377265A1 (en) 2014-12-25
MX2013011092A (es) 2013-12-06
KR20140009437A (ko) 2014-01-22
CO6771448A2 (es) 2013-10-15
PE20140964A1 (es) 2014-08-17
TN2013000388A1 (en) 2015-01-20
EP2691156A1 (en) 2014-02-05
US20120276123A1 (en) 2012-11-01
AP2013007046A0 (en) 2013-08-31
CA2827787A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
ECSP12012105A (es) Antídotos de Anticoagulantes
CY1121497T1 (el) Συριγγα
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
ECSP13012997A (es) Antídotos anticoagulantes
CR20150329A (es) Inmunoglobulinas heterodiméricas
BR112014030278A2 (pt) anticorpo, e, composição.
ECSP14027269A (es) Picolinamidas macrocíclicas como fungicidas
CL2015001054A1 (es) Métodos de cultivo de microorganismos en condiciones mixotrópicas no axénicas.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
UY34652A (es) Anticuerpos humanos frente a toxinas de clostridium difficile
BR112014031412A2 (pt) método de preparação de uma composição, composição e seu uso, e kit.
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
UY34372A (es) Moléculas de ácido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleópteros.
BR112014000232A8 (pt) primeira composição, segunda composição e artigo
UY35795A (es) Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran
CL2012001927A1 (es) Anticuerpo capaz de neutralizar la actividad de un anticoagulante de dabigatran; método de fabricación de anticuerpo; kit que comprende al anticuerpo.
CY1124956T1 (el) Συριγγα
MX2013007212A (es) Piñata semi-armable con centro de cerrado automático.
TH1201003589B (th) แอนติโดทของสารต้านการแข็งตัวของเลือด
NI201200143S (es) Motocicleta
TR201106798U (tr) Gizli çekmece rayı için kenetleme mekanizması.
TH1401000566B (th) แผ่นเส้นใยและวิธีการสำหรับการผลิตสิ่งที่คล้ายคลึงกัน